Почетна › Рак на бели дробови со не-мали клетки › Вирџинија › Charlottesville
Клинички испитувања за Рак на бели дробови со не-мали клетки во Charlottesville, VA
Една студија за Рак на бели дробови со не-мали клетки бара учесници на локација во или блиску до Charlottesville. Отворете ја за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Се регрутираФаза 1
- Exelixis Clinical Site #66, Charlottesville
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Се регрутираФаза 2
- University of Virginia, Charlottesville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Се регрутираФаза 3
- UVA Comprehensive Cancer Center, Charlottesville
- UVA Health Fontaine Research Park, Charlottesville
- University of Virginia, Charlottesville
- и уште 1
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Се регрутираФаза 2
- University of Virginia Cancer Center, Charlottesville
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Се регрутираФаза 3
- University of Virginia Health System, Charlottesville
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Се регрутираФаза 2/3
- University of Virginia Health System, Charlottesville
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Се регрутираФаза 3
- Clinical Study Site, Charlottesville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Се регрутираФаза 3
- University of Virginia Health System, Charlottesville
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Се регрутираФаза 1/2
- University of Virginia Cancer Center, Charlottesville
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Се регрутираФаза 3
- Research Site, Charlottesville
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Се регрутираФаза 3
- University of Virginia, Charlottesville
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
Се регрутираФаза 2
- UVA Comprehensive Cancer Center, Charlottesville
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Се регрутираФаза 2
- University of Virginia Cancer Center, Charlottesville
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2
- University of Virginia Cancer Center, Charlottesville
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2/3
- University of Virginia Cancer Center, Charlottesville
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Се регрутираФаза 2
- University of Virginia Health System, Charlottesville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Се регрутираФаза 1/2
- University of Virginia, Charlottesville
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Се регрутираФаза 2
- University of Virginia Health System, Charlottesville
GEMINI-NSCLC: NSCLC Biomarker Study
Се регрутираНабљудувачка студија
- University of Virginia, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Се регрутираНабљудувачка студија
- Massive Bio SYNERGY-AI site, Charlottesville
A Study of NX-1607 in Adults With Advanced Malignancies
Се регрутираФаза 1
- University of Virginia, Charlottesville
Испитувања за Рак на бели дробови со не-мали клетки во други градови
- Houston, TX145 студии
- New York City, NY121 студија
- Arlington, VA104 студии
- Nashville, TN97 студии
- Boston, MA90 студии
- Los Angeles, CA87 студии
- St. Louis, MO73 студии
- Chicago, IL61 студија
- Baltimore, MD60 студии
- San Antonio, TX59 студии
- Columbus, OH57 студии
- Washington, DC55 студии
Други студии во Charlottesville
- Акутна миелоидна леукемија16 студии
- Рак на простата15 студии
- Рак (сите типови)13 студии
- Рак на ендометриумот13 студии
- Метастатски карцином13 студии
- Рак на бели дробови13 студии
- Срцева слабост12 студии
- Колоректален карцином10 студии
- Карцином на јајниците10 студии
- Дијабетес тип 19 студии
- Рак на дојка9 студии
- Карцином на панкреасот9 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.